NCT01664000View on ClinicalTrials.gov

A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

February 29, 2016

Conditions
Solid Tumors
Interventions
DRUG

thioureidobutyronitrile

Kevetrin (thioureidobutyronitrile)

Trial Locations (1)

02215

Dana-Farber / Beth Israel Deaconess Medical Center / Harvard Cancer Center, Boston

Sponsors
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

Cellceutix Corporation

INDUSTRY